Source:http://linkedlifedata.com/resource/pubmed/id/19207964
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2009-2-11
|
pubmed:abstractText |
Recently several randomized trials involving exclusively HCV 2 and 3 patients have explored the possibility of reducing the duration of therapy with PEG IFNs and ribavirin to 12-16 weeks. Among these, the largest studies (ACCELERATE, NORTH-C and NORDynamIC) have failed to demonstrate, by intention-to-treat analysis, that short treatment is non-inferior to the standard duration of 24 weeks originated by phase 3 trials. Even though obtaining univocal conclusions from these studies are difficult to obtain due to some critical differences (trial design, genotypes 2/3 ratio, rate of cirrhosis at baseline, ribavirin dose, assays to detect HCV-RNA etc), all have proved that a rapid virological response (HCV-RNA negative at 4 weeks) is the strongest predictor of SVR. Therefore, excluding risk factors for virological relapse at baseline, and identifying in the early phase of treatment, features related to a sustained response, the decision to reduce the duration of treatment to less than 24 weeks in HCV-2 and 3 patients can be response-guided appropriately. Ongoing studies will assess whether extended 48 week regimens can benefit non-RVR patients with HCV 2 or 3, especially those with more severe fibrosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1478-3231
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
29 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
31-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19207964-Antiviral Agents,
pubmed-meshheading:19207964-Drug Administration Schedule,
pubmed-meshheading:19207964-Drug Therapy, Combination,
pubmed-meshheading:19207964-Genotype,
pubmed-meshheading:19207964-Hepacivirus,
pubmed-meshheading:19207964-Hepatitis C, Chronic,
pubmed-meshheading:19207964-Humans,
pubmed-meshheading:19207964-Interferon-alpha,
pubmed-meshheading:19207964-Polyethylene Glycols,
pubmed-meshheading:19207964-Recombinant Proteins,
pubmed-meshheading:19207964-Ribavirin
|
pubmed:year |
2009
|
pubmed:articleTitle |
Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.
|
pubmed:affiliation |
Cattedra di Gastroenterologia, Di.Bi.M.I.S., University of Palermo, Palermo, Italy. giutar@alice.it
|
pubmed:publicationType |
Journal Article,
Review
|